The Athelas team is beyond excited to share that our flagship device, the Athelas Home, has been cleared by the FDA for home-use indication. From a small volume of blood, the Athelas Home measures White Blood Cells and Neutrophil percentages remotely within a patient’s home or other near-patient setting. The system also has the ability to flag the presence of Blast Cells, Immature Cells, and other Abnormal Cell types often found in liquid tumors.
The Athelas Home represents a step-function leap in how chronically ill patients can be managed remotely in America. It adds to Athelas’s fast-growing remote patient monitoring (RPM) platform, and further cements us as the market leader in delivering in-home care for health systems.
The Athelas Home represents a step-function leap in how chronically ill patients can be managed remotely in America.
In cancer care, patients are highly immunosuppressed during treatment, with heavily depleted White Blood Cell and Neutrophil levels. Due to immunosuppressive chemotherapy or immunotherapy, a patient’s risk for Febrile Neutropenia, Infections, and Hospitalizations is incredibly high; directly impacting treatment + outcomes. With the Athelas Home, oncologists and other clinicians can remotely monitor a patient’s neutrophil levels to ensure safer oncology treatment. Crashes in Neutrophil counts accompanied by fever require immediate interventions such as G-CSF, antibiotic cocktails, dose-adjustment, quarantine, amongst other acute changes. On the flip side, rapid improvement in Neutrophil counts can often allow for faster follow ups and intensifying treatment.
As such, we see the Athelas Home becoming an essential tool in the management of Cancer patients remotely.
In Refractory Schizophrenia populations, the medication clozapine is highly efficacious in treating psychosis, but carries a risk for agranulocytosis (drop in White Blood Cells and Neutrophils). In order to stay on the medication, patients require weekly or monthly venous blood draws. The Athelas Home device enables simpler fingerprick monitoring of WBC and NEUT% levels to initiate and comply with clozapine therapy. Athelas is partnered with HLS Therapeutics (manufacturer of brand Clozaril) to bring fingerprick White Blood Cell and Neutrophil level monitoring directly to near-patient settings. Today, the Athelas Home platform is standard of care for Clozapine treatment.
In other immunosuppressed populations - such as patients utilizing autoimmune drugs, HIV drugs, or those with chronic idiopathic Neutropenia - the Athelas Home similarly allows for key remote monitoring of a patient’s immune system.
The Athelas Home technology platform also has the ability to measure Platelets, Hemoglobin, full White Blood Cell differential, Malaria, Blast Cells, and other key hematological parameters - all currently in clinical trials or FDA review.
In the coming months, we will be launching more sensor + software tools to give clinicians superpowers in the management of patient health.
To get in touch about deploying Athelas Remote Patient Monitoring for your patients, message contact@athelas.com
